



Press Release

February 16, 2026

TOWA PHARMACEUTICAL CO., LTD.

Towa Receives Manufacturing and Marketing Approval for Generic Drugs

Osaka, Japan, February 16, 2026 – Towa Pharmaceutical Co., Ltd. (Head office: Kadoma, Osaka; President: Itsuro Yoshida) has received approval from the Ministry of Health, Labour and Welfare to manufacturing and marketing the following five ingredients and seven items of generic drugs. DESLORATADINE OD TABLETS and BILASTINE OD TABLETS were approved for the first time as ingredients of generics.

« The list of approved products »

1. DAPAGLIFLOZIN TABLETS

Product name	DAPAGLIFLOZIN TABLETS 5mg/10mg “TOWA”
Brand-name drugs	Forxiga 5mg/10mg tablets

2. DESLORATADINE OD TABLETS

Product name	DESLORATADINE OD TABLETS 5mg “TOWA”
Brand-name drugs	DESALEX Tablets 5mg (Different dosage form)

3. BILASTINE OD TABLETS

Product name	BILASTINE OD TABLETS 20mg “TOWA”
Brand-name drugs	Bilanoa OD tablet 20mg

4. LUBIPROSTONE CAPSULES

Product name	LUBIPROSTONE CAPSULES 24µg “TOWA”
Brand-name drugs	Amitiza Capsules 24mcg

5. ARIPIPRAZOLE TABLETS

Product name	ARIPIPRAZOLE TABLETS 1mg “TOWA”
Brand-name drugs	ABILIFY Tablets 1mg

6. ARIPIPRAZOLE ORAL SOLUTION

Product name	ARIPIPRAZOLE ORAL SOLUTION 1mg “TOWA”
Brand-name drugs	ABILIFY Oral Solution 0.1%

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

[Inquiries]

Public Relations and Investor Relations Department, Towa Pharmaceutical Co., Ltd.

2-11 Shinbashi-cho, Kadoma, Osaka 571-8580, Japan

Email: kouhou@towayakuhin.co.jp